Riferimento:
Leuk Res. 2012 Jun;36(6):735-41.
Autori:
Yoshida H, Imamura T, Fujiki A, Hirashima Y, Miyachi M, Inukai T, Hosoi H.
Fonte:
Leuk Res. 2012 Jun;36(6):735-41.
Anno:
2012
Azione:
L'induzione/attivazione di CCAAT/esaltatore del legame della proteina alfa (C/EBPα) nella leucemia mielocita acuta (AML) è stata studiata usando una combinazione di acido all-trans retinoico (ATRA) e RAD001 (Everolimus).
Target:
ATRA-RAD001/leucemia mielocitica acuta.
ABSTRACT
CCAAT/enhancer binding protein alpha (C/EBPα) induction induces monocytic differentiation even in acute myeloid leukaemia (AML). In this study, the induction/activation of C/EBPα in myelomonocytic AML was investigated using a combination of all-trans retinoic acid (ATRA) and RAD001 (Everolimus), a mammalian target of rapamycin complex 1 (mTORC1) inhibitor. Combining these agents increased PU.1, C/EBPε and C/EBPα expression, increased the p42/p30 C/EBPα ratio, and decreased C/EBPα phosphorylation at serine 21, and was accompanied by growth inhibition, induction of CD11b expression and apoptosis in AML cell lines. Thus, agents that induce sufficient levels of C/EBPα expression might be useful in treating AML.
Sostanze: